Alimera Sciences Announces First Quarter 2021 Financial Results
Alimera Sciences Announces First Quarter 2021 Financial Results
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the first quarter of 2021. Alimera will host a conference call on April 29, 2021, at 9:00 a.m. ET to discuss these results.
“In the first quarter of 2021 we experienced our typical seasonal downturn in revenue versus the fourth quarter of 2020 as well as the continued impact of the COVID-19 pandemic. We expect revenue to rebound in Q2 behind encouraging month-over-month growth in the U.S. as well as the late Q1 demand in some of our key international markets,” said Rick Eiswirth, Alimera’s President and Chief Executive Officer. “Additionally, we are pleased with our ongoing geographic expansion including availability of ILUVIEN® in the Nordic countries during the first quarter and our recently announced exclusive license agreement with Ocumension for Greater China and the Western Pacific.”
First Quarter 2021 Financial Results
Consolidated net revenue decreased 23% to approximately $11.2 million, compared to $14.5 million for Q1 2020.
U.S. net revenue decreased 21% to approximately $5.6 million for Q1 2021 compared to $7.1 million for Q1 2020. The decrease was due to the continuing impact of the COVID-19 pandemic on patients’ ability to return to retina offices. End user demand, which represents units purchased by physicians and pharmacies from our distributors, decreased 14% to 737 units during Q1 2021 compared to 855 units during Q1 2020.
The difference between GAAP revenue and end user demand is due to the timing of distributor purchases from Q1 2021 versus Q1 2020. During Q1 2021, our distributors purchased approximately 9% fewer units than were sold to end users while during Q1 2020, our distributors purchased approximately 3% more units than were sold to end users.
International net revenue decreased 25% to approximately $5.6 million for Q1 2021, compared to approximately $7.5 million for Q1 2020. The decrease in international net revenue in Q1 2021 compared to Q1 2020 was due to strong distributor sales in Q1 2020 coupled with the continuing effects of the COVID-19 pandemic, which created lower overall end user demand, and slower than anticipated inventory turnover in distributor markets.
Total operating expenses were approximately $12.1 million for Q1 2021, compared to approximately $12.4 million for Q1 2020.
Net Loss and Adjusted EBITDA
Net loss for Q1 2021 was $(3.6) million, compared to net loss of approximately $(1.2) million for Q1 2020. “Adjusted EBITDA,” a non-GAAP financial measure defined below, was approximately $(1.3) million for Q1 2021, compared to Adjusted EBITDA of approximately $1.3 million for Q1 2020.
Net Loss per Share
Basic and diluted net loss per share for Q1 2021 was approximately $(0.63) compared to basic and diluted net loss per share of $(0.24) for Q1 2020.
Cash and Cash Equivalents
On March 31, 2021, Alimera had cash and cash equivalents of approximately $8.3 million dollars, compared to $11.2 million in cash and cash equivalents on December 31, 2020.
On April 14, 2021 Alimera announced it had received $20.0 million from Ocumension Therapeutics, consisting of a $10.0 million upfront payment for the rights to develop and commercialize Alimera’s 0.19mg fluocinolone acetonide intravitreal injection for the treatment of diabetic macular edema and other retina diseases (excluding uveitis) in the Greater China territory and other Western Pacific countries under Ocumension’s own distinct trademark, and a $10.0 million purchase of Alimera’s common stock in a private offering.
Definition of Non-GAAP Financial Measure
For purposes of this press release, “Adjusted EBITDA” is defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, losses on extinguishment of debt and severance expenses. Please refer to the sections of this press release entitled “Non-GAAP Financial Measure” and “Reconciliation of GAAP Net Income or Loss to Non-GAAP Adjusted EBITDA.”
Conference Call to Be Held April 29, 2021
A live conference call will be hosted on April 29, 2021 at 9:00 a.m. EST by Rick Eiswirth, president and chief executive officer, and Phil Jones, chief financial officer, to discuss Alimera’s financial results and provide an update on corporate developments. Please refer to the information below for conference call dial-in information and webcast registration.
Conference date: Thursday, April 29, 2021 9:00 a.m. EST
Conference dial-in: 877-839-2190
International dial-in: 412-317-9583
Conference Call Name: Alimera Sciences (Nasdaq: ALIM) First Quarter 2021 Financial Results Conference Call
Conference Call Pre-registration: Participants are asked to pre-register for the call by navigating to: https://dpregister.com/sreg/10155027/e6f02ce52b
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.
The conference call will also be available through a live webcast which is also available through the company’s website.
Live Webcast URL: https://services.choruscall.com/links/alimera210429.html
A replay will be available on Alimera’s website, www.alimerasciences.com, under “Investor Relations” one hour following the live call.
Conference Call replay: US Toll Free: 1-877-344-7529
International Toll: 1-412-317-0088
Canada Toll Free: 855-669-9658
Replay Access Code: 10155027
End Date: July 29, 2021
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
Non-GAAP Financial Measure
This press release contains a discussion of a non-GAAP financial measure, as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. Alimera reports its financial results in compliance with GAAP but believes that the non-GAAP measure of Adjusted EBITDA provides useful information to investors regarding Alimera’s operating performance. Alimera uses Adjusted EBITDA in the management of its business. Accordingly, Adjusted EBITDA for the three months ended March 31, 2021 and 2020 has been presented in certain instances excluding items identified in the reconciliations provided in the table entitled “Reconciliation of GAAP Net Income or Loss to non-GAAP Adjusted EBITDA.” GAAP net income or loss is the most directly comparable GAAP financial measure to Adjusted EBITDA.
Adjusted EBITDA, as presented, may not be comparable to similarly titled measures reported by other companies because not all companies may calculate Adjusted EBITDA in an identical manner. Therefore, Adjusted EBITDA is not necessarily an accurate measure of comparison between companies.
The presentation of Adjusted EBITDA is not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgments by management in determining this non-GAAP financial measure.
Forward Looking Statements
This press release contains, and the conference call in which executives of Alimera will discuss this press release may include, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the Company’s expectation that the ILUVIEN sales will rebound in the second quarter of 2021 despite the continuing COVID-19 pandemic. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change these expectations, and could cause actual results to differ materially from those projected in these forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to, uncertainties associated with (a) the continued effects of COVID-19 on the ability or willingness of patients to visit their retina specialists for ILUVIEN injections; (b) current and future governmental orders and policies adopted by healthcare facilities to address the COVID-19 pandemic, and the duration of these limitations; (c) the recent resurgence of the pandemic in both Europe and parts of the U.S.; (d) the emergence of COVID-19 variants that may increase the transmissibility of the coronavirus or be more deadly, or both; (e) the success or failure of the vaccine campaigns in Alimera’s markets; (f) when in fact the pandemic will subside enough to permit Alimera’s operations to return to its prior growth trajectory, and whether Alimera will be able to achieve that goal when given that opportunity; as well as the other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2020, which is on file with the SEC and is available on the SEC’s website at http://www.sec.gov. Additional factors will also be described in those sections of Alimera’s Quarterly Report on Form 10-Q for the first quarter of 2021, to be filed with the SEC soon. Alimera undertakes no obligation to publicly update or revise any of the forward-looking statements made in this press release, whether as a result of new information, future events or otherwise, except as required by law. Therefore, you should not rely on these forward-looking statements as representing Alimera’s views as of any date after today.
|For investor inquiries:||For media inquiries:|
for Alimera Sciences
for Alimera Sciences
ALIMERA SCIENCES, INC.
CONSOLIDATED BALANCE SHEETS
|March 31,||December 31,|
|Cash and cash equivalents||$||8,266||$||11,208|
|Accounts receivable, net||15,702||17,200|
|Prepaid expenses and other current assets||3,736||3,718|
|Total current assets||30,330||34,906|
|Property and equipment, net||1,559||1,638|
|Right of use assets, net||619||720|
|Intangible asset, net||12,359||12,838|
|Deferred tax asset||720||753|
|Paycheck Protection Program (PPP) loan||1,778||1,481|
|Finance lease obligations||215||209|
|Total current liabilities||11,209||12,348|
|Finance lease obligations — less current portion||451||514|
|Other non-current liabilities||3,535||3,563|
|COMMITMENTS AND CONTINGENCIES|
|Series A Convertible Preferred Stock||19,227||19,227|
|Additional paid-in capital||366,092||365,830|
|Common stock warrants||370||370|
|Accumulated other comprehensive loss — foreign currency translation adjustments||(1,150||)||(553||)|
|TOTAL STOCKHOLDERS’ DEFICIT||(11,960||)||(7,978||)|
|TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT||$||45,587||$||50,855|
ALIMERA SCIENCES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(in thousands, except share and per share data)
|Three Months Ended
|COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION||(1,562||)||(1,927||)|
|RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES||3,213||2,883|
|GENERAL AND ADMINISTRATIVE EXPENSES||3,413||2,983|
|SALES AND MARKETING EXPENSES||4,818||5,870|
|DEPRECIATION AND AMORTIZATION||638||654|
|(LOSS) INCOME FROM OPERATIONS||(2,430||)||218|
|INTEREST EXPENSE AND OTHER||(1,343||)||(1,292||)|
|UNREALIZED FOREIGN CURRENCY GAIN (LOSS), NET||125||(81||)|
|NET LOSS BEFORE TAXES||(3,648||)||(1,155||)|
|PROVISION FOR TAXES||—||(43||)|
|NET LOSS PER SHARE — Basic and diluted||$||(0.63||)||$||(0.24||)|
|WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and diluted||5,755,424||4,980,722|
RECONCILIATION OF GAAP MEASURES TO NON-GAAP ADJUSTED MEASURES
GAAP NET INCOME OR LOSS TO NON-GAAP ADJUSTED EBITDA
|Three Months Ended
|GAAP NET LOSS||$||(3,648||)||$||(1,198||)|
|Adjustments to net loss:|
|Interest expense and other||1,343||1,292|
|Provision for taxes||—||43|
|Depreciation and amortization||638||654|
|Stock-based compensation expenses||262||440|
|Unrealized foreign currency exchange (gains) losses||(125||)||81|
|NON-GAAP ADJUSTED EBITDA||$||(1,335||)||$||1,312|